Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

ICU muscle mystery: new study aims to uncover why patients stay weak

NCT ID NCT00937001

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why over half of ICU patients develop severe muscle weakness that can last for months or years. Researchers will use muscle biopsies, ultrasound, and strength tests on 50 critically ill adults to find better ways to diagnose and track this condition. The goal is to understand the problem, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Nov 2008

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Patients will be included if they are adult, patients in a medical and/or surgical ICU receiving treatment for any of the following: * respiratory failure, or * cardiogenic or septic shock. Exclusion Criteria: 1. Cumulative ICU time \> 5 days in the past 30 days, not including the current ICU stay, as this might create a state of flux regarding patients' cognitive baseline. 2. Severe cognitive or neurodegenerative diseases that prevent a patient from living independently at baseline, including mental illness requiring institutionalization, acquired or congenital mental retardation, known brain lesions, traumatic brain injury, cerebrovascular accidents with resultant moderate to severe cognitive deficits or ADL dependency, Parkinson's disease, Huntington's disease, severe Alzheimer's disease or dementia of any etiology. 3. ICU admission post cardiopulmonary resuscitation with suspected anoxic injury. 4. An active substance abuse or psychotic disorder, or a recent (within the past 6 months) serious suicidal gesture necessitating hospitalization. This exclusion will enrich follow-up rates by avoiding patients with whom it is particularly challenging to maintain long-term contact. 5. Blind, deaf, or unable to speak English, as these conditions would preclude our ability to perform the follow-up evaluation interviews. 6. Overly moribund and not expected to survive for an additional 24 hours and / or withdrawing life support to focus on comfort measures only. 7. Prisoners. 8. Patients who live further than 200 miles from Nashville and who do not regularly visit the Nashville area. 9. Patients who are homeless and have no secondary contact person available. This exclusion will enrich follow-up rates by avoiding patients with whom it is particularly challenging to maintain long-term contact. 10. The onset of the current episode of respiratory failure, cardiogenic shock, or septic shock was \> 72 hours ago. 11. Patients who have had cardiac bypass surgery within the past 3 months (including the current hospitalization). 12. Patients with known Neuromuscular disease prior to admission. 13. BMI \> 40 or patient size that will not make percutaneous muscle biopsy and muscle ultrasound possible. 14. Patients with a platelet count of less than 30,000.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University

    Nashville, Tennessee, 37323, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.